Ms Eilísh Hardiman:

When Dr. Goldman came on board as the chief medical officer, this element was one of the things to progress. Before that, we had a process whereby the research and ethics committee did take some elements relating to clinical ethics. We also have a clinical ethicist in CHI and if there were issues of that nature that needed to be considered a group would come together. What Dr. Goldman has put in place has meant that, as opposed to responding to issues whenever they were formally raised, they will be put into a more formal process. There was a form of ethics support for staff who raised those particular issues before it was set up as a formal committee.